An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.

Anri InakiTohru ShigaYoshito TsushimaMegumi JingujiHiroshi WakabayashiDaiki KayanoNorihito AkataniTakafumi YamaseYuji KunitaSatoru WatanabeTomo HiromasaHiroshi MoriKenji HirataShiro WatanabeTetsuya HiguchiHiroyasu TomonagaSeigo Kinuya

Published in: Annals of nuclear medicine (2021)

A single dose 131I-mIBG therapy was well tolerated by patients with PPGL, and statistically significantly reduced catecholamine levels compared to the threshold response rate, which may lead to an improved prognosis for these patients.

Keyphrases

phase ii
clinical trial
open label
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
double blind
phase iii
stem cells
peritoneal dialysis
study protocol
placebo controlled
patient reported
smoking cessation